<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301911</url>
  </required_header>
  <id_info>
    <org_study_id>XPTN-Ia-1.0</org_study_id>
    <nct_id>NCT01301911</nct_id>
  </id_info>
  <brief_title>Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer</brief_title>
  <official_title>A Phase I Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cipatinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. This&#xD;
      study is designed to evaluate the safety and tolerability of cipatinib in patients with HER2&#xD;
      positive or uncertain advanced breast cancer:&#xD;
&#xD;
        1. To evaluate the safety and tolerability of cipatinib, and the maximum tolerated dose&#xD;
           (MTD) and dose-limiting toxicity (DLT)&#xD;
&#xD;
        2. To determine the pharmacokinetic profile of cipatinib and its metabolites&#xD;
&#xD;
        3. To assess preliminary antitumor activity&#xD;
&#xD;
        4. To determine preliminary regimen for phase II study&#xD;
&#xD;
        5. To determine the relation of expression of HER-1 and HER-2 to the antitumor activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum-tolerated dose (MTD) regimen of cipatinib will be defined as the maximum dose level at which no more than one subject out of six experiences a dose-limiting toxicity (DLT) after completing one treatment cycle.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cipatinib pharmacokinetic parameters may include AUC, Cmax, Tmax, and t1/2.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR).</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cipatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipatinib</intervention_name>
    <description>Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily</description>
    <arm_group_label>Cipatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 18 and ≤ 65 years.&#xD;
&#xD;
          -  ECOG performance status of 0 to 1.&#xD;
&#xD;
          -  Life expectancy of more than 3 months.&#xD;
&#xD;
          -  Histologically or cytologic confirmed HER2 positive or uncertain advanced breast&#xD;
             cancer that is not curable with available therapies.&#xD;
&#xD;
          -  Screening laboratory values within the following parameters:&#xD;
&#xD;
               -  ANC: ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelet count: ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin: ≥ 9.0 g/dL&#xD;
&#xD;
               -  Serum albumin: ≥ 2.5 g/dL&#xD;
&#xD;
               -  Total bilirubin: ≤ 1.5 x upper limit of normal, ULN&#xD;
&#xD;
               -  ALT and AST: ≤ 1.5 x ULN&#xD;
&#xD;
               -  Serum creatinine: ≤ 1.0 x ULN&#xD;
&#xD;
               -  Creatinie clearnce rate: ≥ 50 mL/min&#xD;
&#xD;
               -  Cholesterol≤7.75 mmol/L and triglyceride≤2.5 x ULN&#xD;
&#xD;
               -  LVEF: ≥ 50%&#xD;
&#xD;
               -  QTcF: &lt; 470 ms&#xD;
&#xD;
          -  Recovery from all clinically significant AEs related to prior therapies. Duration from&#xD;
             the latest therapy is more than 6 weeks for nitroso or mitomycin, or more than 4 weeks&#xD;
             for operation, radiotherapy, cytotoxic agents or molecular targeting.&#xD;
&#xD;
          -  Ability or willingness to swallow tablets, no dysfunction of gastrointestinal&#xD;
             absorption.&#xD;
&#xD;
          -  All subjects who are not surgically sterile or postmenopausal must agree and commit to&#xD;
             the use of a reliable method of birth control for the duration of the study and for 6&#xD;
             months after the last dose of test article. For women of child bearing potential, a&#xD;
             negative urine or serum pregnancy test result before initiating cipatinib.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with third space fluid that can not be controled by drainage or other&#xD;
             methods.&#xD;
&#xD;
          -  Steroid treatment for more than 50 days, or in need of long-term use of steroids.&#xD;
&#xD;
          -  Subjects with uncontrol hypokalemia and hypomagniesemia before study entry.&#xD;
&#xD;
          -  Subjects can not interrupt the using of the drugs that may cause QT prolongation&#xD;
             during study.&#xD;
&#xD;
          -  Subjects with meningioma, or with active central nervous system metastases as&#xD;
             indicated by clinical symptoms.&#xD;
&#xD;
          -  Subjects with liver metastases which ALT or AST &gt; 1.5 x ULN.&#xD;
&#xD;
          -  Treated or treating with EGFR or HER2 TKIs before study entry.&#xD;
&#xD;
          -  Receiving any other antitumor therapy.&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Known history of hypersensitivity to cipatinib or any of it components.&#xD;
&#xD;
          -  Ongoing infection (determined by investigator).&#xD;
&#xD;
          -  Subjects had any heart disease: coronary artery disease, arrhythmia need to treat,&#xD;
             heart failure, LVEF &lt; 50%, and any other heart disease that is determined as unfit for&#xD;
             this study by investigator, etc.&#xD;
&#xD;
          -  Evidence of significant medical illness that in the investigator's judgment will&#xD;
             substantially increase the risk associated with the subject's participation in and&#xD;
             completion of the study. Examples include, but are not limited to, hypertension,&#xD;
             severe diabetes, or thyroid disease.&#xD;
&#xD;
          -  Known history of neurological or psychiatric disease, including epilepsy or dementia.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>December 20, 2012</last_update_submitted>
  <last_update_submitted_qc>December 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer, Advanced</keyword>
  <keyword>Cipatinib</keyword>
  <keyword>phase I</keyword>
  <keyword>HER2 positive or uncertain advanced breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

